Ohtuvayre denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for ohtuvayre are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Ohtuvayre as Duplicate Therapy

Ohtuvayre (ensifentrine) is an inhaled bronchodilator approved by the FDA for maintenance treatment of COPD. It combines two distinct mechanisms of bronchodilation in a single inhaled agent. Aetna's duplicate-therapy denial typically fires when their system detects that you are already taking one or more inhaled bronchodilators — such as a long-acting beta-agonist (LABA) or long-acting muscarinic antagonist (LAMA) — and concludes that adding Ohtuvayre provides no additional benefit over what you already have.

This logic is often flawed for Ohtuvayre specifically, because its mechanism of action is different from both LABA and LAMA agents. Whether combination use is appropriate in your individual case is a clinical question that belongs to your pulmonologist, not to Aetna's automated review system.

## Why This Is Appealable

A duplicate-therapy determination requires Aetna to demonstrate that the requested drug provides no clinically meaningful benefit beyond existing therapy. When your prescriber has documented a clinical rationale for adding Ohtuvayre — such as inadequate symptom control or exacerbation frequency on current therapy — that rationale directly rebuts the duplicate-therapy conclusion. Request Aetna's written duplicate-therapy definition and the specific clinical basis for the finding.

## Federal Appeal Framework

• Internal appeal: File within the timeframe stated on your Explanation of Benefits (EOB) — typically 180 days. Request the complete clinical criteria and the identity of the reviewing clinician's specialty.
• External review (ACA §2719): After a final internal denial, you are entitled to independent review by an accredited IRO. Standard window is approximately four months from the final denial; expedited review (72-hour decision) is available when delay would seriously harm your health.
• ERISA §503 (employer plans): Full-and-fair review rights apply; you may request all documents Aetna used.

## Documentation to Gather

1. COPD diagnosis and severity — spirometry results, COPD staging per your pulmonologist's assessment, and current symptom burden (CAT score or mMRC grade from your chart — do not fabricate numbers; use what is in the actual record). 2. Current medication list — a complete list of all bronchodilators and inhaled therapies you are taking, with start dates. 3. Inadequate response documentation — clinic notes documenting ongoing symptoms, exacerbation history, or rescue inhaler use despite current therapy. 4. Prescriber medical-necessity letter — a letter from your pulmonologist explaining why Ohtuvayre's distinct mechanism provides additive benefit that is not duplicative of your current regimen. 5. FDA-approved label — the Ohtuvayre prescribing information, to demonstrate the approved indication and the mechanistic distinction.

## Criteria-Mapping Structure

Obtain Aetna's published duplicate-therapy and COPD maintenance drug policies. List each criterion they require for coverage. In the adjacent column, cite the specific chart document that addresses it — dated clinic notes, spirometry reports, and the prescriber letter. Attach as labeled exhibits.